Algernon Pharmaceuticals A Aktie

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), along with the Centre for Human Drug Research (CHDR), will present its Phase 1 stroke study data at the Interdisciplinary Conference on Psychedelic Research being held June 6-8, 2024 in Haarlem, the Netherlands. AGN Neuro is the world's first company to investigate DMT for the treatment of stroke and its ability to promote neuroplasticity in the healing of brain injuries. » Mehr auf globenewswire.com

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has finalized the acquisition of its NP-120 (Ifenprodil) research program by US-based Seyltx Inc in a deal valued at US$2 million in cash along with a 20% equity stake in Seyltx. Ifenprodil is a potential first-in-class treatment for chronic cough, targeting the NMDA receptor to suppress the urge to cough. » Mehr auf proactiveinvestors.com

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has said it is considering the potential spin-off of its NP-120 (Ifenprodil) chronic cough research program. The company said it has engaged Maxim Group LLC to provide financial advisory and investment banking services with a focus on identifying and evaluating potential mergers and acquisitions (M&A) and strategic opportunities including the potential spin-off. » Mehr auf proactiveinvestors.com